Archives for January, 2021

Dr. Larry Ereshefsky Coauthors Article on Cost-Effectiveness of MDD Treatment, Vortioxetine

Larry Ereshefsky, Pharm.D., Chief Scientific Officer of Apex Innovative Sciences, has published more than 130 peer-reviewed scholarly articles and abstracts. His latest work, “Cost-effectiveness of vortioxetine compared with levomilnacipran and vilazodone in patients with major depressive disorder switching from an initial antidepressant,” has been published in the medical journal, Expert Review of Pharmacoeconomics & Outcomes…

Read More

2021 Pharma Conference eCards from Apex Innovative Sciences

Our annual eCards are here and updated for 2021. Download the neuroscience-focused card as well as the general medical version. We’re excited to connect with you during these conferences. Virtual and Zoom meetings will keep us safer for now, and we’re hopeful that we’ll return to in-person conversations in the near future. Please check each…

Read More

Apex Innovative Sciences Supports Three Major COVID-19 Vaccine Trials

MARLTON, N.J. and GARDEN GROVE, Calif., Jan. 5, 2021 — Apex Innovative Sciences (Apex) and its affiliates are proud to announce their participation in three COVID-19 vaccine studies. With East and West Coast operations and six state-of-the-art clinical trial facilities, Apex is strongly positioned to pivot from its core central nervous system (CNS) business and…

Read More